Arterial plaque can be reduced, but not eliminated entirely. Intensive cholesterol-lowering medication, combined with diet and exercise changes, can shrink plaque volume by a modest but meaningful amount and, just as importantly, stabilize existing plaque so it’s far less likely to rupture and cause a heart attack. Complete reversal isn’t realistic with current treatments, but slowing progression and reshaping plaque composition is well-supported by clinical evidence.
What “Getting Rid of Plaque” Actually Means
When most people picture clearing plaque from arteries, they imagine scrubbing pipes clean. The reality is more nuanced. Plaque is a complex mix of cholesterol, inflammatory cells, calcium, and scar tissue embedded in the artery wall. Treatment works on three levels: shrinking overall plaque volume, changing its composition to make it more stable, and halting further growth.
Stable plaque has a thick fibrous cap and a small fatty core. Dangerous plaque has a thin cap over a large pool of lipids, making it prone to rupture. When plaque ruptures, it triggers a blood clot that can block the artery entirely, causing a heart attack or stroke. So the goal isn’t just making plaque smaller. It’s making whatever plaque remains less likely to cause a catastrophic event.
Cholesterol-Lowering Medication Is the Strongest Tool
High-intensity statin therapy is the most studied and effective approach to plaque regression. In the REVERSAL trial, patients on a high dose of a potent statin saw a 0.4% reduction in total plaque volume over 18 months, while those on a moderate statin saw plaque grow by 2.7%. The SATURN trial showed reductions of 3.2% to 4.8% in total plaque volume over two years. Those numbers sound small, but they correspond to measurable changes in artery narrowing and, more importantly, in the composition of the plaque itself.
Statins don’t just shrink plaque. Imaging studies show they reduce the soft, fatty components inside plaque (the parts most likely to rupture) while increasing the dense, calcified portions that are structurally stable. The fibrous cap covering the plaque thickens, creating a stronger barrier. In practical terms, the plaque becomes more like a hard scar and less like a fragile blister.
For people with established heart disease, current guidelines from the American Heart Association recommend driving LDL cholesterol below 70 mg/dL with high-intensity statin therapy. For those at very high risk (multiple heart events, diabetes plus other risk factors), the target drops to below 55 mg/dL, often requiring additional medications on top of statins.
When Statins Aren’t Enough
A newer class of injectable medications called PCSK9 inhibitors can dramatically lower LDL cholesterol beyond what statins achieve alone. A meta-analysis of randomized trials found that adding a PCSK9 inhibitor significantly increased fibrous cap thickness by about 29 micrometers compared to standard therapy. That thicker cap is a direct marker of plaque stabilization. These drugs are typically reserved for people who can’t reach their cholesterol targets on statins alone or who can’t tolerate statins at all.
Another option is ezetimibe, a pill that blocks cholesterol absorption in the gut. Guidelines recommend it as a first add-on when statins alone aren’t lowering LDL enough.
Targeting Inflammation Directly
Cholesterol drives plaque growth, but inflammation is what makes plaque dangerous. Even people with well-controlled cholesterol can have heart attacks if their arteries are chronically inflamed.
Low-dose colchicine, a decades-old anti-inflammatory drug, has emerged as a tool for reducing cardiovascular events. It works by blocking a specific inflammatory pathway that activates signaling molecules responsible for driving plaque progression. In two large trials, low-dose colchicine reduced the risk of major cardiovascular events by more than 30% compared to placebo. It also lowered markers of inflammation in the blood and may decrease plaque volume directly. This is a prescription medication, not something to start on your own, but it represents a genuinely new approach to managing arterial disease beyond just lowering cholesterol.
Diet Changes That Measurably Affect Arteries
A Mediterranean diet supplemented with nuts produced measurable plaque regression in a landmark study. Participants eating this way saw their carotid artery wall thickness decrease by 0.084 mm, while people eating a standard low-fat diet saw their artery walls get thicker. Plaque height also shrank in the Mediterranean diet group while it grew in the control group. These are direct measurements of artery structure, not just blood test improvements.
The Mediterranean pattern emphasizes olive oil, nuts, fish, vegetables, legumes, and whole grains while limiting red meat, processed foods, and refined carbohydrates. The combination of unsaturated fats, fiber, and anti-inflammatory compounds appears to work on multiple pathways simultaneously. No single food or supplement replicates the effect of the overall dietary pattern.
Exercise Works at Any Intensity
A randomized trial comparing high-intensity interval training to standard moderate exercise in people with stable coronary artery disease found that both groups experienced a 13% to 14% reduction in lipid content within their coronary plaques after six months. The key finding: favorable plaque remodeling happened regardless of exercise intensity. You don’t need to push yourself to near-maximum heart rates to get arterial benefits.
What matters more is consistency. Regular aerobic activity improves blood vessel function, reduces inflammation, lowers blood pressure, and helps control blood sugar, all of which slow plaque progression. The specific activity matters far less than doing it regularly.
What About Supplements?
Vitamin K2 is widely marketed online as a way to reverse arterial calcification. The theory sounds plausible: K2 activates a protein that directs calcium away from arteries and into bones. But when this was tested rigorously in a randomized, double-blind trial, two years of vitamin K2 plus vitamin D supplementation made no difference in arterial or aortic valve calcification compared to placebo. The calcification scores increased at virtually the same rate in both groups. Despite the supplement activating the target protein as expected (blood markers confirmed this), it didn’t translate to any measurable change in the arteries.
Other commonly promoted supplements like fish oil, garlic extract, and nattokinase lack strong clinical trial evidence for plaque regression. Some may modestly improve cholesterol or blood pressure, but none have been shown to shrink or stabilize existing plaque in well-designed human studies.
Surgical and Procedural Options
For arteries that are severely narrowed and causing symptoms like chest pain or reduced blood flow, procedures can physically open the blockage. Angioplasty uses a balloon to compress plaque against the artery wall, usually followed by placing a stent (a small wire mesh tube) to keep the artery open. This doesn’t remove plaque; it pushes it aside and scaffolds the artery.
Atherectomy is a procedure that actually shaves or vaporizes plaque from inside the artery. However, outcomes have been disappointing. In the CAVEAT trial, atherectomy led to higher rates of heart attack (8.9% vs. 4.4%) and death (2.2% vs. 0.6%) compared to standard angioplasty at one year, with no improvement in the rate of repeat procedures. It’s now used mainly in specific situations where stent placement is difficult, such as heavily calcified arteries in the legs.
These procedures treat the symptoms of severe blockages but don’t address the underlying disease process. Without medication and lifestyle changes afterward, new plaque will continue to form.
Tracking Your Progress
A coronary artery calcium (CAC) score, measured by a quick CT scan, quantifies the amount of calcified plaque in your heart arteries. In the large MESA study, the average person’s calcium score increased by about 25 units per year. People whose scores jumped by 300 or more units annually had nearly four times the risk of coronary events and over six times the risk of heart attacks compared to those with no progression.
A rising calcium score doesn’t necessarily mean treatment is failing. Statins can actually increase calcium scores in the short term because they convert soft, dangerous plaque into denser, more stable calcified plaque. That’s a favorable change even though the number goes up. For this reason, calcium scores are most useful as a baseline screening tool rather than a way to monitor treatment response. Cholesterol levels, inflammatory markers, and imaging of plaque composition give a more accurate picture of whether therapy is working.